Contract research firm Charles River Laboratories announced Thursday that it exceeded financial projections for the first quarter, driven by growing demand for pharmaceutical development services.
The company’s strong performance signals a potential recovery for contract research organizations as biotechnology and pharmaceutical companies resume drug discovery activities and safety testing following a period of reduced spending.
Contract research organizations, known as CROs, provide specialized services to biotech companies including managing clinical trial components like patient enrollment, data gathering, and ensuring regulatory compliance.
Chief Executive Officer Birgit Girshick expressed satisfaction with the results, stating: “We are pleased to deliver on our first-quarter financial targets, and remain well positioned to generate improving results over the course of the year.”
The company posted adjusted earnings of $2.06 per share for the quarter ending March 28, exceeding the analyst consensus estimate of $1.94 per share based on LSEG data.
Total revenue reached $995.8 million for the quarter, surpassing Wall Street’s projected $977.5 million.
The discovery and safety assessment division generated $596.9 million in revenue, representing a 0.7% increase from the previous year’s first quarter.
Charles River maintained its annual adjusted earnings guidance of $10.80 to $11.30 per share.
The positive results align with industry trends, as competitor IQVIA Holdings also reported stronger-than-anticipated quarterly performance earlier this week, supported by robust demand for clinical research and technology solutions from pharmaceutical partners.
